Effects of ACE gene polymorphism on vitamin D therapy according to parathyroid hormone level in patients on hemodialysis

Advances in Therapy

Volumn 23, Issue 5, 2006, Pages 778-786

  Kulah, Eyup ^a,c   Sezer, Siren ^b   Uyar, Murathan ^b   Arat, Zübeyde ^b   Ozdemir, Fatma Nurhan ^b  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c Faculty of Arts and Sciences   (Turkey)

Author keywords

Angiotensin converting enzyme; Gene polymorphism; Hemodialysis; Parathyroid hormone; Vitamin D therapy

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALUMINUM; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CALCIUM; CALCIUM ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENOMIC DNA; NITROGEN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; UREA; VITAMIN D;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ARTICLE; CALCIUM BLOOD LEVEL; CREATININE BLOOD LEVEL; DEMOGRAPHY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENETIC DIFFERENCE; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHARMACOGENETICS; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT PLANNING; UREA NITROGEN BLOOD LEVEL;

FEMALE; GENOTYPE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES; VITAMIN D; VITAMINS;

EID: 33845653156     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850318     Document Type: Article

References (21)

1. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496-502.
2. Silver J. Molecular mechanism of secondary hyperparathyroidism. Nephrol Dial Transplant. 2000;15(suppl 15):2-7.
3. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1226-1237.
4. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
5. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
6. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation. 1994;90:2622-2628.
7. Nakai K, Itoh C, Miura Y, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation. 1994;90:2199-2202.
8. Rudberg S, Rasmussen LM, Bangstad HJ, Osterby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care. 2000;23:544-548.
9. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int. 2003;23:111-115.
10. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997;30:1289-1294.
11. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens. 1995; 8:894-901.
12. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):387-392.
13. Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999;33:73-81.
14. Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites. Nephrol Dial Transplant. 2000;15(suppl 5):18-24.
15. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int. 2001;60:46-54.
16. Abdi R, Tran TB, Zee R, Brenner BM, Milford EL. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 2001;72:726-729.
17. Akiba T, Ando R, Kurihara S, Heishi M, Tazawa H, Marumo F. Is the bone mass of hemodialysis patients genetically determined? Kidney Int Suppl. 1997;62:S69-S71.
18. Altun B, Kiykim AA, Seyrantepe V, et al. Association between activated renin angiotensin system and bone formation in hemodialysis patients: is the bone mass genetically determined by ACE gene polymorphism? Ren Fail. 2004;26:425-431.
19. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1998;83:1766-1770.
20. Alonso GC, Naves Diaz ML, Diaz-Corte C, Fernandez Martin JL, Cannata Andia JB. Vitamin D receptor gene (VDR) polymorphisms: effect on bone mass, bone loss and parathyroid hormone regulation. Nephrol Dial Transplant. 1998;13(suppl 3):73-77.
21. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab. 1992;75:988-992.